Connect with us

Policy

UK MPs welcome psychedelic research, call for scheduling review

Published

on

Photo by Jurica Koletić on Unsplash

In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in the country, welcoming the government’s commitment to psychedelic research.

The report highlights barriers to research that are preventing the UK from developing its own psychedelic research industry “which has an emerging and growing global market.”

Exploring topics such as legislative framework, the Government’s 10-year Drugs Strategy, county lines, health and criminal justice-led harm reduction, cannabis and more, the report recommends that the Government balances its criminal justice response to drugs with an increased public health response.

See also  UK advisory body issues rapid response on psychedelic research

It highlights that the Misuse of Drugs Act 1971 – which came into force more than 50 years ago – is in urgent need of reform as it has “failed to prevent drug use and has failed to reduce drug-related deaths and drug-related offending”, as well as disproportionately impacting ethnic minorities. 

Restrictions in the Act and its supporting Act, the Misuse of Drugs Regulations 2001, regulate how drugs are licensed and handled – and psychedelic compounds such as LSD and psilocybin – are included as Schedule 1 drugs under it. This makes licensing costs for research incredibly high, creating barriers to scientific knowledge and advancements. 

While these barriers do exist, a number of initiatives have nonetheless been established in the UK looking at psychedelic research, such as a partnership between King College London’s Institute for Psychiatry, Psychology and Neuroscience, South London NHS Foundation Trust and COMPASS Pathways to investigate the use of psychedelics for Treatment-Resistant Depression (TRD).

See also  UK MPs demand answers as Drugs Minister dodges psilocybin debate

With this rise in clinical evidence that psychedelic medicines may hold promise as treatments for a number of mental health conditions, the MPs call for an urgent reclassification of psychedelic compounds from Schedule I to Schedule II.

“We welcome the UK Government’s commitment to reducing barriers to researching psychedelic drugs under Schedule 1 to the 2001 Regulations.” the report states. 

“Pending the outcomes of the ACMD’s ongoing review of Schedule 1 controlled drugs, we recommend the UK Government urgently moves psychedelic drugs to Schedule 2 in order to facilitate research on the medical or therapeutic value of these drugs.”

And continues: “Beyond the potential benefit psychedelics may have to health, these barriers may also prevent the UK from developing its own psychedelic research industry, which has an emerging and growing global market. The barriers researchers face may therefore stymie our understanding of controlled drugs, undermine innovations in medical treatment and undermine the UK as a global leader in science and medicine.”

While the Advisory Council on the Misuse of Drugs (ACMD) is currently conducting a review of barriers to researching Schedule 1 Drugs – which is allegedly in “advanced” stages – the report recommends that a wider review is required, recommending that the Home Office “must reform the classification system and the scheduling system based on the findings of that review” and that updated assessments should be conducted every 10 years. 

Speaking to Psychedelic Health, the independent non-profit reform group, Drug Science, which provided evidence for the report, stated: “Drug Science were pleased that the evidence we gave to the Select Committee played a significant role in this report. 

“Specifically, we support their call for reform of the drug laws to reduce harms and facilitate research particularly the re-scheduling of psychedelics like psilocybin for treatment purposes. 

“It is difficult to comprehend that such a well-researched and thoughtful report should be simply dismissed by the Home Office. Their rejection of policies proven to save lives confirms the urgent need for a change in the current processes, and the need for a health-centred approach. 

“Drug Science hopes that the Department of Health will be more supportive.”

Timmy Davis, Psychedelics Lead at CDPRG and Policy Director at Psilocybin Access Rights (PAR), added: “The number of influential voices within parliament calling for the rescheduling of psilocybin and other psychedelics continues to grow. The Home Affairs Committee are the most recent to chime in, echoing and amplifying those from the public and civil society, including the Royal College of Psychiatrists and two of the most influential UK mental health charities, CALM and SANE.

“There has never been a clear voice of opposition, but the Home Office continues to hide behind an upcoming report by the Advisory Council on the Misuse of Drugs (ACMD). This report will make recommendations on the removal of barriers to researching Schedule 1 drugs (the first iteration of which was commissioned in 2017), despite this being completely unnecessary for the Home Office to take action to reschedule.

“It is another question entirely whether the recommendations of the ACMD’s report, which will almost certainly not recommend rescheduling, will be enacted by the Home Office who have a history of ignoring or acting in contradiction to their advice.

“The newly released Home Affairs Committee report on the other hand is clear – 50 years on from the enactment of the Misuse of Drugs Act 1971, a wholesale review of UK drugs policy is long overdue. Amongst a variety of measures to better deal with the risks posed by currently controlled drugs, such as the facilitation of festival drug checking and diamorphine-assisted treatment, they have recommended a one-time review of the Class and Schedule status of all controlled drugs. If psychedelics were found to be better placed within Schedule II or lower, research and prescription would be greatly facilitated.

“It would rectify the unjustified levels of control inflicted upon these substances, aligning scheduling and classification with the most recent evidence of harms and utility. Since the psychedelics were first controlled, there has been no review of the evidence – and given the number of times such recommendations have been made, such large-scale reform is an unlikely outcome of the release of this particular report.

“That said, it is becoming increasingly clear that the appetite for reform within parliament is quickly becoming a reflection of the views of the UK public, who want to see increased access to psychedelic-assisted therapies. It is gratifying to see the impact that our Psilocybin Rescheduling Project is continuing to have within parliament.

“As the Psilocybin Access Rights campaign continues to increase public pressure, and the CDPRG continues to troubleshoot the misgivings within the Home Office, we remain optimistic that HMG will grasp the scale of the opportunity and reschedule psilocybin ahead of market authorisation.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Policy

Now is the time for psychedelic access, says campaigner

Published

on

Now is the time for psychedelic access, says campaigner

Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses. 

In the face of critics, Hodges has said now is the time for safe access to psychedelics.

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.” 

Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.

The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.

Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever. 

Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.

“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”

Continue Reading

Policy

Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published

on

Transform Drugs releases book: How to regulate psychedelics

UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.

While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.

The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline. 

Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.

Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing. 

“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe. 

“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and  making moves to regulate for non-medical adult use.”

Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics. 

“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”

Proposals for regulation

The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.

These include:

  • Private use, home cultivation, foraging and not-for-profit sharing.
  • Membership-based non-for-profit associations for plant-based products.
  • Licensed production and retail adaptable to different products and environments
  • Regulated commercial guided or supervised use

Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.

The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.

To read the book, please visit transformdrugs.org/.

Continue Reading

Policy

Oakland ballot seeks to legalise medical psychedelics

Published

on

Oakland ballot seeks to legalise medical psychedelics

Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses. 

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

See also  Australia reschedules psilocybin and MDMA

Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.

The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.

See also  CDPRG discusses the UK's Reschedule Psilocybin campaign

The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs. 

Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.

When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement. 

Signature collecting will begin in early December.

Continue Reading

Trending